Eli Lilly has now named a filing window for retatrutide in the United States: a Biologics License Application to the FDA in the first quarter of 2027, announced on 23 July 2026 alongside topline results from two more Phase 3 trials. That's a US date, from a company press release — not a regulator's decision. But it matters more to Australians than it looks, because retatrutide TGA approval is unlikely to begin with an Australian evaluation from scratch. Australia has a specific mechanism for leaning on overseas work, and understanding it tells you far more about the local sequence than any guessed release date.

Retatrutide TGA approval starts somewhere else

The TGA maintains a list of comparable overseas regulators (CORs) — jurisdictions whose assessments it will use to avoid duplicating evaluation work. That list includes the US FDA and the European Medicines Agency, alongside the UK's MHRA, Swissmedic, Health Canada, Japan's PMDA and Singapore's HSA.

The practical effect: when a sponsor brings a new medicine to Australia that a COR has already assessed, the TGA can run a shortened process rather than re-evaluating the entire dossier. So the FDA's handling of retatrutide isn't just American news. It's an input into the Australian file.

Retatrutide remains investigational. It is not approved for sale anywhere, and it is not on the Australian Register of Therapeutic Goods. Nothing below is a prediction that it will be — only an explanation of the machinery that would have to run. For the underlying pharmacology, see what is retatrutide; for the trial programme behind the filing, see our clinical trials page.

How the COR pathway actually works

The TGA offers two main COR approaches for prescription medicines, with different target timeframes for evaluation and decision:

  • COR-A — 120 working days. The fastest route, with strict entry requirements.
  • COR-B — 175 working days. Allows the TGA to evaluate certain data itself, in addition to the label, Product Information and Risk Management Plan.

Both are target timeframes measured in working days, not calendar days — 120 working days is roughly 24 weeks of business days before you account for anything else.

The one-year clock nobody mentions

The detail worth knowing: COR-A is designed for cases where the full marketing approval from the overseas regulator is no older than one year. In other words, the fastest Australian route is built around acting soon after an overseas decision, not years later. If a sponsor lets an overseas approval age, that specific door narrows.

None of this happens automatically. The TGA does not register medicines on its own initiative — Eli Lilly Australia would have to lodge an application, and eligibility for any expedited approach is assessed, not assumed.

What Mounjaro's Australian paperwork actually shows

The closest local precedent is Lilly's own tirzepatide. The TGA's registration record for Mounjaro shows the product first entering the ARTG on 23 December 2022 for the diabetes indication.

The weight-management indication came later and separately: registered 10 September 2024, following an evaluation that commenced 3 October 2023. That's roughly eleven months from the start of evaluation to registration for a single indication extension — on a molecule the TGA already knew well, from a sponsor with an established Australian presence.

Two things follow for anyone tracking retatrutide in Australia. First, indications arrive one at a time; Lilly has said it now has the data package to pursue submissions for obesity, knee osteoarthritis pain and obstructive sleep apnoea, and there is no reason to assume those move as a single block. Second, "registered" is not the same as "affordable" — PBS listing is a separate process run by a different body, which we cover on our Australia page.

What we genuinely don't know

We don't know when, or whether, an Australian application will be lodged. We don't know which COR approach would be used, or whether priority determination would be sought. We don't know the first Australian indication. Anyone publishing a specific Australian approval date is guessing.

What we can say is that the COR framework makes the FDA's Q1 2027 filing a milestone with Australian relevance — and that the one-year design of COR-A rewards sponsors who move promptly after an overseas decision rather than waiting.

If you want the regulatory steps as they're confirmed rather than as they're rumoured, join the free updates list. We also track the tolerability data as it's published on our safety page.

FAQ

Is retatrutide TGA approved?

No. Retatrutide is an investigational medicine and is not on the Australian Register of Therapeutic Goods. Eli Lilly has publicly stated it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027; that is a US filing plan, not an Australian approval.

Can the TGA approve retatrutide before the FDA does?

There is no rule requiring an overseas approval first — but the TGA's comparable overseas regulator (COR) pathways are specifically built around using assessments from regulators such as the FDA and EMA to shorten evaluation. Lilly has not announced an Australian application, so the sequence is unknown.

How long does TGA approval take after an overseas approval?

Under the COR pathways, the TGA's target evaluation and decision timeframes are 120 working days for COR-A and 175 working days for COR-B. COR-A is intended for cases where the overseas full marketing approval is no more than one year old. These are targets, not guarantees, and the sponsor must apply first.

Does TGA approval mean retatrutide will be on the PBS?

No. Registration on the ARTG and subsidy through the Pharmaceutical Benefits Scheme are separate decisions made through separate processes. Lilly's tirzepatide was registered in Australia for diabetes in December 2022 and for weight management in September 2024, with subsidy handled independently of registration.

Sources

This article is for general information only and is not medical advice. Retatrutide is investigational and has not been approved by the TGA. Speak with a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.